|
|
|
篇目详细内容 |
|
【篇名】 |
Expression of PC-cell-derived growth factor in breast cancer |
|
【刊名】 |
Frontiers of Medicine in China |
|
【刊名缩写】 |
Front. Med. China |
|
【ISSN】 |
1673-7342 |
|
【EISSN】 |
1673-7458 |
|
【DOI】 |
10.1007/s11684-009-0085-7 |
|
【出版社】 |
Higher Education Press and Springer-Verlag |
|
【出版年】 |
2009 |
|
【卷期】 |
3
卷4期 |
|
【页码】 |
426-430
页,共
5
页 |
|
【作者】 |
Haiping SONG MD;
Lan SHI MD;
Chunping LIU MD;
Tao HUANG MD;
|
|
【关键词】 |
PC-cell-derived growth factor; breast neoplasms; clinical markers |
【摘要】 |
|
This study is mainly aimed at evaluating the expression of PC-cell-derived growth factor (PCDGF) in breast cancer and breast adenofibroma, and to compare with other commonly used clinical pathological indices, then to investigate the diagnostic and targeted therapeutic purpose of PCDGF in breast cancer tissue. In this study, we detected the expression of PCDGF, p53 and CerbB-2 in breast cancer tissue and the expression of PCDGF in breast adenofibroma tissue by immunohistochemical method, and analyzed the relationship between them. We found that PCDGF was expressed in most breast cancer tissue, but was not in breast adenofibroma tissue, and the expression of PCDGF was related with the tumor’s pathological category and the expression of estrogen receptor (ER) and progesterone receptor (PR) and p53, but there was no statistical dependability between PCDGF and cerbB-2. From this study, we predict that PCDGF may serve as a marker in the secondary diagnosis of breast cancer, and may participate in the generation and differentiation of breast cancer cells, and become an effective target of therapy for breast cancer. |
|
